0

NOW ENROLLING: Phase 3 SURPASS-IPF for people with idiopathic pulmonary fibrosis. Click to learn more about our clinical trial.

Skip to Content
Celea Therapeutics
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us
Celea Therapeutics
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us

Deupirfenidone Compared to Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis: ELEVATE IPF Phase 2b Trial. ATS International Conference. 2025. Maher TM, et al. [Oral Presentation]

Publication
May 20
Written by Christine Mackenzie
Christine Mackenzie
Previous
Previous

PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial

Next
Next

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

Celea Therapeutics

6 Tide Street, Suite 400
Boston, MA 02210


info@celeatx.com

DEUPIRFENIDONE
PATIENTS & PHYSICIANS
ABOUT US
CAREERS
NEWS & PUBLICATIONS
CONTACT

© 2026 Celea Therapeutics, Inc. All rights reserved. Expanded Access Policy

The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether deupirfenidone is safe and effective. No regulatory agency has made any such determination that deupirfenidone is safe or effective for use by the general public for any indication.